| کلیدواژههای انگلیسی مقاله |
COVID-19, Medicine, SARS-CoV-2, Viruses, What&,rsquo s Known People reporting long-term symptoms associated with COVID-19, (Long COVID Syndrome), have complained of various problems, including respiratory, cardiovascular, musculoskeletal, and neurological problems. However, the extent and characteristics of such post-acute phase lingering symptoms are not clear yet. What&,rsquo s New Long COVID syndrome (LCS) is a frequent and significant and at times, disabling condition. In this large population-based study, we reported that LCS has significant associations with sex (more observed in women), respiratory symptoms at the onset, and the severity of the illness (length of hospital stay). IntroductionIt has been more than a year since the start of the coronavirus disease-2019 (COVID-19) pandemic caused by severe acute respiratory syndrome (SARS)-coronavirus-2 (SARS-CoV-2). During the early stages of the pandemic, people were mainly concerned with its fatality, and later on, everybody noticed the psychosocial consequences of the pandemic. More recently, people have recognized the post-acute phase lingering symptoms of the disease. 1, , 2, Many COVID-19 survivors have reported a variety of persistent signs and symptoms after the acute phase of the illness. 3, Although there is no universally accepted terminology and definition for this condition, some authors have considered the persistence of symptoms (fatigue, breathlessness, cough, joint pain, chest pain, muscle aches, headache, and several others, which could not be attributed to any other cause) beyond two weeks for mild disease, beyond four weeks for moderate to severe illness, and beyond six weeks for critically ill patients as &,ldquo long COVID syndrome&,rdquo (LCS). 4, The National Institute for Health and Clinical Excellence (NICE), the Scottish Intercollegiate Guidelines Network (SIGN), and the Royal College of General Practitioners (RCGP) have jointly developed the following definitions, a. ongoing symptomatic COVID-19, signs and symptoms of COVID-19 from 4 to 12 weeks and b. post-COVID-19 syndrome, signs and symptoms developed during or after an infection consistent with COVID-19, which continue for more than 12 weeks and are not explained through an alternative diagnosis. 5, The etiology and the biological underpinnings of LCS are not clear yet. However, SARS-CoV-2 invades many tissues and has multi-organ and multi-system impacts. 6, In addition, the persistence of viremia and psychological factors may also contribute to the development of LCS. 7, , 8, People reporting long-term symptoms associated with COVID-19 have complained of various problems, including respiratory, cardiovascular, musculoskeletal, and neurological problems. 9, - 12, Meanwhile, the extent, characteristics, and the associated factors of such post-acute phase lingering symptoms are not entirely clear yet.In the current population-based study, we investigated the full spectrum of symptoms of patients suffering from LCS (based on the literature review and consultations with experts in the field). We also examined the chronicity of the symptoms to add to the existing literature. Finally, we scrutinized the potential risk factors associated with the development of LCS in a large cohort of patients with documented COVID-19 to add to the existing literature.MethodsParticipantsIn this retrospective, uncontrolled, and observational cohort work, all the consecutive adult patients, 18 years or older, were referred and admitted to healthcare facilities (55 centers) throughout Fars province (located in the South of Iran with a population of 4,851,000 people) from February19, 2020 to November 20, 2020. The Shiraz University of Medical Sciences Institutional Review Board approved this study (IR.SUMS.Rec.1399.022). All the participants consented orally, (We conduct the research to investigate the lingering symptoms of the COVID-19. Do you agree to participate in this study and answer our questions over the phone?).All the patients had a confirmed COVID-19 diagnosis with a positive result on Real-Time polymerase chain reaction (PCR) testing of nasopharyngeal and oropharyngeal samples. All the samples were taken at the emergency room.Data CollectionFor each patient, admitted with a diagnosis of COVID-19, the following data were collected at the emergency room by the admitting physician and entered into a database (on admission), age, sex, presence of fever, cough, respiratory distress, muscle pain, change in mental status, loss of smell, dizziness, headache, abdominal pain, nausea, vomiting, and anorexia. Other collected data included, PCR test results and admission to a hospital ward [COVID-specific ward, intensive care unit (ICU), or others]. Underlying chronic health problems such as renal, liver, cardiac, or neurological, and diabetes mellitus (DM), cancer, hypertension (HTN), and pulmonary disorders were also collected (self-declared). No data were available about the hospital course of the patients (laboratory test results, management, complications). However, the outcome was also recorded in the database, as dead or discharged. The diagnosis dates of the patients were from 19 February 19, 2020 to November 20, 2020. In a telephone conversation with the discharged patients, made by the last 12 authors, at least three months after their illness (from March 1 to 14, 2021), we investigated their current health status and obtained their information, if they agreed to participate and answer the questions (consented orally, We are conducting research to investigate the lingering symptoms of the COVID-19. Do you agree to participate in this study and answer our questions over the phone?). We randomly selected every other adult patient in our database (alternate patients in the database sorted by their phone numbers). If someone did not answer, in the second attempt, we selected the previous patient in the list, who was skipped initially, because of not responding. Figure 1, illustrates the inclusion process of the participants.Figure 1. The figure shows the recruitment process of the study. A data gathering form ( appendix 1 ___________ ) was specifically designed for the purpose of data collection, and all the team members were instructed by the first author, on how to inquire the data consistently and in the same manner. The first part of the form (eight questions) collected the demographic data and some confirmatory data (date of admission and underlying disorders before COVID-19) to cross-check with the primary database. In the second part (28 questions), we asked if the patient had noticed any problems (cough, fatigue, muscle or joint pain, and headache), or was suffering from any conditions (chronic problems) in the prior week compared with their pre-COVID-19 conditions (any symptoms, complaints, or problems that they did not have before their COVID-19 diagnosis, but appeared after the illness and specifically during the past seven days). The survey was designed and developed as follows, We conducted a literature review and numerous interviews with other participants. We developed the items and conducted an expert validation to assess the clarity and relevance of the items with regard to the construct of interest. For the purpose of this study, we defined LCS as any symptoms, complaints, or problems that the patients did not experience before their COVID-19 diagnosis, but have persistently had during the seven days prior to the follow-up. We specifically asked their complaints during the past seven days in order to minimize the risk of recall bias. Since our work was a retrospective inquiry, we did not study the starting date of the symptoms/problems. We also asked the severity of their complaints (1. Mild and tolerable 2. Moderate 3. Severe and disabling). In the third part of the questionnaire (five questions), we asked the patients to compare their current status (on five items) with their pre-COVID-19 status based on a Likert scale (1. Much worse 2. Somewhat worse 3. The same as before 4 Somewhat better 5. Much better). The following were also asked, 1. ability to perform the activity of daily living 2. concentration and mind workability 3. studying and reading ability 4. quality of life 5. hope for the future. Statistical AnalysesThe SPSS Statistics (IBM Corp., USA, version 25.0) was used. We arbitrarily categorized the patients into two groups (to investigate the longevity and chronicity of the symptoms), a. Group 1, a phone call from three to six months after being diagnosed with COVID-19 b. Group 2, a phone call from six to 12 months after the illness. Values were presented as mean&,plusmn SD for continuous variables and as the number (percent) of subjects for categorical variables. Based on the previous studies, the following variables were selected as the risk factors potentially associated with long COVID syndrome, sex (men and women), age (mean&,plusmn SD), length of hospital stay (mean&,plusmn SD), respiratory problems at the onset, neurological problems at the onset, gastrointestinal problems at the onset, pre-existing chronic medical problems, and ICU admission. Pearson Chi square, Fisher&,rsquo s exact test, t test, Bonferroni correction test, and binary logistic regression analysis model were employed for statistical analyses, then significant variables from univariate analyses were entered into the logistic regression analysis model. Odds ratios (ORs) and 95% confidence intervals (CIs) were estimated. A P value (two-sided) of less than 0.05 was considered to be significant.ResultsGeneral Characteristic of the PatientsSince the start of the pandemic until November 20, 2020, 13,165 patients with confirmed COVID-19 were referred to 55 healthcare facilities in Fars province 1694 people died (case fatality rate, 12.8%) and 11,471 individuals (adults and children) were discharged from the hospitals. In the follow-up phase of this study, 4,681 adult patients discharged from the hospitals agreed to participate 427 people (8.4%) of those, who were contacted refused to participate in this study (figure 1,). The respondents included, 2634 patients (56%) and 2047 family members/care-givers (44%). The participants included 2478 men (52.9%) and 2203 women (47.1%), and their mean age was 52&,plusmn 15 years. Clinical Characteristics of the PatientsManifestations of COVID-19 on admission were as follows, respiratory/pulmonary in 4182 (89.3%) [hypoxemia (SpO2&,lt 93% by Pulse Oximeter reading) in 56.6%, respiratory distress in 54.1%, cough in 52.8%, and chest pain in 5%] neurological in 818 (17.5%) [headache in 14.1%, loss of smell in 2.2%, change in mental status in 1.7%, loss of taste in 1.1%] and gastrointestinal (GI) in 731 (15.6%) patients [nausea in 8.6%, vomiting in 5.1%, diarrhea in 4,9%, and abdominal pain in 3.2%]. Several patients had non-specific manifestations [fever in 41%, myalgia in 39.5%, anorexia in 10.9%, and dizziness in 4%]. A minority [482 (10.3%)] of the patients needed ICU admission. Duration of the hospital stay was as short as a few hours (in eight patients) to as long as 112 days, two months or more in eight patients, (mean&,plusmn SD, 7&,plusmn 6 days). In addition, 1766 patients (37.7%) had pre-existing chronic medical conditions (19.9% HTN, 16.1% DM, 10.6% cardiac problems, 2.6% asthma, 1.9% renal problems, 1.5% other pulmonary disorders, and 1.2% cancer). Long COVID ManifestationsWe called 1996 (42.6%) patients, diagnosed with COVID-19 six to 12 months prior, and 2685 (57.4%) people with the infection three to six months prior. In total, 2915 (62.3%) people reported symptoms/complaints, 1774 (66%) had shorter follow-ups and 1141 (57%) with longer follow-ups (P=0.0001) had long-lasting problems. Table 1, represents the symptoms/complaints of the patients in these two groups. In general, all the symptoms/complaints were reported by both groups however, some of the symptoms/complaints were significantly less frequent in those with an infection for a longer time (weakness, muscle pain, fatigue, sleep difficulty, palpitation, cough, brain fog, exercise, and walking intolerance). Table 2, shows the severity of the reported symptoms/complaints. While most of the symptoms/complaints were rated as mild and tolerable by the participants, a minority of the patients reported severe and disabling problems. There were no significant differences between the two groups of the patients (those diagnosed with COVID-19 from the previous six to 12 months versus people with the infection from the previous three to six months) with respect to the severity of the symptoms of LCS ( table 3,). Other reported chronic problems (not mentioned in the tables) included, Hair loss in 102 (2%), new-onset DM in 18, new-onset HTN in 11, loss of libido in two, and new-onset chronic renal failure in one patient.Clinical Manifestations3-6 months follow-up, N=2685 n (%)6-12 months follow-up, N=1996 n (%)P valueWeakness543 (20%)278 (14%)0.0001Muscle pain562 (21%)291 (15%)0.0001Joint pain491 (18%)296 (15%)0.002Fatigue847 (32%)493 (25%)0.0001Sleep difficulty453 (17%)254 (13%)0.0001Shortness of breath563 (21%)347 (17%)0.003Chest pain303 (11%)175 (9%)0.005Palpitation304 (11%)166 (8%)0.001Cough272 (10%)139 (7%)0.0001Excess sputum171 (6%)123 (6%)0.808Loss of smell123 (5%)92 (5%)0.944Loss of taste78 (3%)54 (3%)0.722Sore throat124 (5%)74 (4%)0.142Headache316 (12%)207 (10%)0.146Dizziness205 (8%)125 (6%)0.083Brain fog319 (12%)161 (8%)0.0001Excess sweating232 (9%)149 (7%)0.160Exercise intolerance694 (26%)396 (20%)0.0001Walking intolerance587 (22%)315 (16%)0.0001Diarrhea73 (3%)42 (2%)0.214Abdominal pain88 (3%)56 (3%)0.393Anorexia104 (4%)65 (3%)0.303Weight loss251 (9%)130 (7%)0.001Weight gain147 (5%)101 (5%)0.598After Bonferroni correction, the significant P value is at &,lt 0.002 |
| نویسندگان مقاله |
Ali Akbar Asadi-Pooya |
Epilepsy Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
Ali Akbari |
Department of Anesthesiology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
Amir Emami |
Burn & Wound Healing Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
Mehrzad Lotfi |
Medical Imaging Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
Mahtab Rostamihosseinkhani |
Epilepsy Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
Hamid Nemati |
Epilepsy Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
Zohreh Barzegar |
Epilepsy Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
Maryam Kabiri |
Epilepsy Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
Zahra Zeraatpisheh |
Epilepsy Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
Mohsen Farjoud-Kouhanjani |
Epilepsy Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
Anahita Jafari |
Epilepsy Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
Fateme Sasannia |
Epilepsy Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
Shayan Ashrafi |
Epilepsy Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
Masoume Nazeri |
Epilepsy Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
Sara Nasiri |
Epilepsy Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
Mina Shahisavandi |
Epilepsy Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
|